Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | ITGAL | P20701 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | CRHBP | P24387 | 2/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7627453 | 0.66 | ABCG2 (0.55) | ABCG2ITGB2ICAM1ITGALGAA | |
| SCHEMBL6959135 | 0.65 | ABCG2 (0.62) | ALOX5ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL335978 | 0.65 | — | — | |
| SCHEMBL20068 | 0.65 | — | — | |
| SCHEMBL27872 | 0.65 | — | — | |
| SCHEMBL5460351 | 0.65 | — | — | |
| SCHEMBL10095220 | 0.65 | ALOX5 (0.48) | ALOX5ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL3412422 | 0.64 | ABCG2 (0.52) | ALOX5ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL154513 | 0.62 | ALOX5 (0.39) | ALOX5GAANPSR1 | |
| SCHEMBL56313 | 0.62 | GAA (0.55) | ALOX5ABCG2ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108601-B | Glycosidase inhibitors | 阿森纽荣股份公司 | 2021-08-20 | — | — | CN | disclosed |
| CN-110770226-A | Sulfoximine glycosidase inhibitors | 阿森纽荣股份公司 | 2020-02-07 | — | — | CN | disclosed |
| US-10227295-B2 | Selective histone deactylase 6 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-9981901-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-05-29 | — | — | US | disclosed |
| US-20170369428-A1 | SELECTIVE HISTONE DEACTYLASE 6 INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9751832-B2 | Selective histone deactylase 6 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
| EP-3150589-A1 | IRE-1A INHIBITORS | MannKind Corporation (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9546149-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2155643-B1 | IRE-1A INHIBITORS | MANNKIND CORP (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2520561-A1 | IRE-1A Inhibitors | MannKind Corporation (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2414322-A2 | POLYAMINE DERIVATIVES | Egen, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110065162-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
| US-7858666-B2 | inositol requiring enzyme 1 (IRE-1 alpha) inhibitors such as 2-hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, relieve protein folding stress by enhancing molecular chaperone activity and protects cells from stress induced apoptosis; autoimmune diseases; anticancer; viricides | MANNKIND CORPORATION (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2155643-A1 | IRE-1A INHIBITORS | MannKind Corporation (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090186893-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2008154484-A1 | IRE-1A INHIBITORS | MANNKIND CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1027347-A2 | 3-AMINOALKYLAMINO-2H-1,4-BENZOXA(THIA-)ZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NEUROGEN CORPORATION (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999023092-A2 | 3-AMINOALKYLAMINO-2H-1,4-BENZOXA(THIA-)ZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NEUROGEN CORPORATION (US) | 1999-05-14 | — | — | WO | disclosed |
| US-5478842-A | Antiinflammatory agents, antiallergens, drugs for treatment of diseases mediated by leukotrienes | ZENECA LIMITED (GB) | 1995-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152206-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ALOX5 4692/4885ABCG2 2312/4885ITGB2 4664/4885 |
| US-20090186893-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ALOX5 4692/4885ABCG2 2312/4885ITGB2 4664/4885 |
| US-20170369428-A1 | SELECTIVE HISTONE DEACTYLASE 6 INHIBITORS | HDAC1, HDAC5, HDAC11 | ALOX5 3360/4885ABCG2 4271/4885ITGB2 2708/4885 |
| US-10227295-B2 | Selective histone deactylase 6 inhibitors | HDAC1, HDAC5, HDAC11 | ALOX5 3360/4885ABCG2 4271/4885ITGB2 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.